A Study to Evaluate ALN-6222 in Participants With Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Alnylam Clinical Trial Information Line
- Phone Number: 1-877-ALNYLAM
- Email: clinicaltrials@alnylam.com
Study Contact Backup
- Name: Alnylam Clinical Trial Information Line
- Phone Number: 1-877-256-9526
- Email: clinicaltrials@alnylam.com
Study Locations
-
-
-
Mount Royal, Canada, H3P 3P1
- Recruiting
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria -
- Is an adult patient with a body mass index ≥30 kg/m^2 to <40 kg/m^2
- Has a hemoglobin A1c <6.5%
Exclusion Criteria -
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN)
- Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
- Has an estimated glomerular filtration (eGFR) of <60 mL/min/1.73m^2 at screening
Note: other protocol defined inclusion / exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants will be administered a single dose of placebo.
|
Placebo will be administered SC.
|
|
Experimental: ALN-6222
Participants will be administered a single dose of ALN-6222.
|
ALN-6222 will be administered subcutaneously (SC).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of Adverse Events
Time Frame: Up to 12 months
|
Up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Concentrations of ALN-6222 in Plasma
Time Frame: Predose and up to 3 days postdose
|
Predose and up to 3 days postdose
|
|
Change from Baseline Protein Markers in Plasma
Time Frame: Predose and up to 12 months postdose
|
Predose and up to 12 months postdose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Alnylam Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ALN-6222-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.